Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals Inc (NQ: CRNX )

44.22 +0.78 (+1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 612,462
Open 43.57
Bid (Size) 43.55 (2)
Ask (Size) 47.70 (1)
Prev. Close 43.44
Today's Range 42.05 - 44.78
52wk Range 15.76 - 49.58
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+24.95%
+24.95%
1 Month
+2.55%
+2.55%
3 Month
+17.58%
+17.58%
6 Month
+48.79%
+48.79%
1 Year
+132.61%
+132.61%

More News

Read More
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
Via Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Crinetics Pharmaceuticals Earnings Preview
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
Via Investor's Business Daily
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
Via Benzinga
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Via Benzinga
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.